title: Antituberculosis therapy-associated cutaneous leukocytoclastic vasculitis.
abstract: Antituberculosis therapy-associated cutaneous leukocytoclastic vasculitis (CLV) has been rarely reported. We describe a case of CLV induced by rifampicin and pyrazinamide. A 14-year-old male diagnosed with disseminated tuberculosis developed purpuric lesions after 1.5 months of treatment. Histopathology was consistent with leukocytoclastic vasculitis. Skin lesion improved after cessation of the two drugs and treatment with corticosteroids.
authors.affiliation: Apollo Center for Advanced Pediatrics, Indraprastha Apollo Hospital, New Delhi 110076, India.
authors.forename: Vidyut
authors.initials: V
authors.lastname: Bhatia
authors.forename: Anupam
authors.initials: A
authors.lastname: Sibal
authors.forename: Shilpy
authors.initials: S
authors.lastname: Rajgarhia
mesh_terms: D000293:Adolescent; D000995:Antitubercular Agents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D011718:Pyrazinamide / Q000009:adverse effects*; D012293:Rifampin / Q000009:adverse effects*; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced*
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D011239:Prednisolone; D012293:Rifampin
keywords: cutaneous leukocytoclastic vasculitis; pyrazinamide; rifampicin